Analysts Set Kura Oncology, Inc. (NASDAQ:KURA) Target Price at $24.50

Kura Oncology, Inc. (NASDAQ:KURA) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $24.50.

Several analysts have commented on the company. Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a report on Friday, June 20th. JMP Securities restated a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a report on Wednesday, June 4th. Cantor Fitzgerald raised shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. Mizuho cut their price target on shares of Kura Oncology from $32.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, May 19th. Finally, UBS Group lowered their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 6th.

Kura Oncology Trading Down 3.0%

Shares of KURA opened at $5.80 on Monday. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $23.48. The company has a market capitalization of $502.11 million, a PE ratio of -2.76 and a beta of 0.40. The stock has a fifty day moving average of $6.18 and a two-hundred day moving average of $7.24. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.07 and a current ratio of 8.07.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million during the quarter, compared to analysts’ expectations of $39.08 million. As a group, analysts forecast that Kura Oncology will post -2.44 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in Kura Oncology during the 4th quarter worth $139,000. Rhumbline Advisers boosted its position in shares of Kura Oncology by 5.2% in the first quarter. Rhumbline Advisers now owns 105,206 shares of the company’s stock worth $694,000 after buying an additional 5,215 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Kura Oncology by 969.9% in the fourth quarter. BNP Paribas Financial Markets now owns 163,559 shares of the company’s stock worth $1,425,000 after buying an additional 148,272 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Kura Oncology by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 635,494 shares of the company’s stock valued at $5,535,000 after buying an additional 10,542 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Kura Oncology by 7.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock valued at $1,147,000 after buying an additional 9,050 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.